Reassessment of T1a cutoff for kidney cancer in the robotic era

Reassessment of T1a cutoff for kidney cancer in the robotic era | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Reassessment of T1a cutoff for kidney cancer in the robotic era Ryohei Yamamoto, Kazuyuki Numakura, Yu Aoyama, Keisuke Okubo, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7281968/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Sep, 2025 Read the published version in Journal of Robotic Surgery → Version 1 posted 12 You are reading this latest preprint version Abstract In 2002, the renal cancer T classification was revised by dividing T1 into T1a and T1b at a 4 cm cutoff. However, local treatment using minimally invasive procedures resulted in better outcomes for tumors smaller than 3 cm, leading the European Association of Urology guideline committee to propose a 3 cm cutoff for T1a/b. Nonetheless, the impact of changing the T1 cutoff on robot-assisted partial nephrectomy (RALPN) has not been fully investigated. This study included 300 out of 335 patients with clinical stage T1 disease who underwent RALPN at our institution between November 2013 and April 2024. We evaluated the discriminative performance of clinical outcomes in each group using tumor diameter cutoffs of 4 and 3 cm. Using a 3 cm cutoff, patients with tumors ≥ 3 cm showed a greater decline in estimated glomerular filtration rate (eGFR) (-9.6% vs. -4.9%, p = 0.003) and a higher incidence of complications (25% vs. 15%, p = 0.040) compared to those with smaller tumors. With a 4 cm cutoff, differences in eGFR decline (-7.8% vs. -6.7%, p = 0.134) and complications (27% vs. 17%, p = 0.100) were not significant. The 3 cm cutoff more accurately predicted complications with a higher area under the curve (0.575 vs. 0.451, p = 0.037). A 3 cm cutoff for the T classification of kidney cancer may more accurately predict postoperative renal function and the risk of complications. kidney cancer clinical T1a classification partial nephrectomy robotic surgery Figures Figure 1 Figure 2 Introduction The Tumour, Node, and Metastasis (TNM) classification based on clinical findings is a reasonable approach for predicting the outcomes of patients with cancer 1 . Historically, the TNM classification for renal cell carcinoma (RCC) has been revised not only to reflect natural history but also in response to advances in diagnostic modalities and treatment options. For instance, in the 2002 Union for International Cancer Control revision, the T1 category was subdivided into T1a and T1b using a 4 cm cutoff diameter, reflecting the increasing number of newly diagnosed organ-confined kidney tumors resulting from the development of imaging modalities such as computed tomography and ultrasonography 2 . The current TNM classification more effectively discriminates between cancer outcomes. For patients with T1 kidney cancer, partial nephrectomy (PN) is equivalent to radical nephrectomy (RN) in terms of cancer control 3 . Moreover, several studies have demonstrated that overall survival rates are better in patients treated with PN than in those treated with RN, largely due to higher comorbidity rates, such as cardiovascular events, in the RN group 4 – 6 . Following the introduction of a robotic platform for kidney surgery, robot-assisted laparoscopic partial nephrectomy (RALPN) has become the standard procedure for T1 RCC 7 . Robotic surgery has obvious advantages over pure laparoscopic nephrectomy, such as more precise resection and proper parenchyma suturing 8 . It also provides favorable oncological outcomes, preserves renal function, and reduces complications 9 . Recent advancements in less-invasive procedures for patients with small renal masses (SRM) may shift management trends for RCC and improve the life expectancy of patients 10 . Cryoablation is a minimally invasive treatment for kidney cancer, particularly indicated for SRMs, especially those 3 cm or less, as it provides excellent local control and low recurrence rates 11 . Cryoablation is often considered in patients with comorbidities, poor surgical candidates, or those with bilateral or multiple tumors 12 . Radiofrequency ablation (RFA) is a minimally invasive treatment for small renal tumors that offers nephron-sparing benefits with lower morbidity compared to surgery. It utilizes thermal energy to destroy cancer cells and is particularly useful for patients who are unsuitable for surgery due to comorbidities 13 . RFA is best suited for older patients, those with single kidneys, bilateral tumors, or multiple comorbidities, and is highly effective for tumors ≤ 3 cm, providing good local control and low recurrence rates 14 . These less-invasive techniques, such as cryoablation and RFA, may represent a paradigm shift in managing SRM and might influence clinical decisions. However, little is known about how different cutoff diameters affect the outcomes of RALPN, which remains the mainstay for managing SRM. Thus, in this study, we aimed to clarify the impact of changing the T1 cutoff from 4 cm to 3 cm in the context of RALPN. Materials and Methods Our institute performed 335 RALPNs for clinical T1 kidney tumors between November 2013 and April 2024. Of these, 300 cases were included in this study after excluding cases of conversion to RN, bilateral tumors, benign histology, and those without follow-up computed tomography (CT) scans (Fig. 1 ). Clinical staging and RENAL scores were determined based on preoperative CT scans. RALPN was performed using either a standard transperitoneal or retroperitoneal approach, depending on the patient’s history of transabdominal surgery, tumor size, and tumor location. PN was performed by clamping the main trunk of the renal artery with a bulldog clamp. The renal vein was clamped in renal hilar tumors. Tumors with a 5-mm surgical margin were resected under 15 mmHg CO 2 pressure; preparation of the renal capsule and tumor surface was conducted at 10 mmHg CO 2 pressure. Inner medullary hemostatic sutures were performed using a running barbed suture, followed by early unclamping and additional hemostatic sutures. Renorrhaphy of the inner and outer layers was performed using 2 − 0 STRATAFIX™ Spiral PDS™ Plus (Ethicon, Raritan, NJ, USA) or 3 − 0 V-Loc™ (Medtronic, Dublin, Ireland), depending on the tumor size and location. All specimens were retrieved using an ENDOPOUCH™ RETRIEVER™ Specimen bag (AutoSuture, Hampshire, UK) through a camera port. Intra- and postoperative complications were categorized based on the Satava 15 and Clavien–Dindo 16 classification systems, respectively, as major or minor complications, and major complications were defined as grade II or higher. Statistical analysis All data are expressed as the median (interquartile range [IQR]). Clinical risk factors associated with longer warm ischemia time (WIT) were screened using univariate analysis. Factors with a p-value of < 0.1 in the univariate analysis were confirmed using logistic regression analysis. All p-values were two-sided, and p < 0.05 was considered statistically significant. All statistical analyses were performed using R software (version 4.4.1; The R Foundation for Statistical Computing, Vienna, Austria). Results Overall characteristics of the patients treated using RALPN Table 1 presents the baseline characteristics of enrolled patients. In this cohort, 73% of patients were male, with a median age of 65 years (IQR, 57–71 years). The median body mass index was 24.5 kg/m² (IQR, 22.5–27.2). The median tumor diameter and RENAL nephrectomy score were 30 mm (IQR, 23–37) and 7 (IQR, 6–8), respectively. The median estimated glomerular filtration rate (eGFR) at baseline was 65.5 mL/min/1.73 m 2 (IQR, 55.5–75.2) (Table 1 ). The median operative time and WIT were 226 min (IQR, 200–255) and 17 min (IQR, 14–20), respectively. The median estimated blood loss (EBL) was 55 mL (IQR, 20–152). A trifecta was achieved in 237 patients (79%), and Clavien–Dindo grade 3A or higher complications occurred in 15 patients (5%). There were no positive cases with resection margins, and five cases (2%) of postoperative recurrence occurred. In the groups below each cutoff diameter, the operative time and WIT were shorter, and the bleeding volume was smaller. Comparison of the cutoff diameter between 4 cm and 3 cm When the cutoff tumor diameter was set at 3 cm, the incidence of postoperative complications was significantly lower in the ≤ 3 cm group compared to the > 3 cm group (15% vs. 25%, p = 0.04). However, using a 4 cm cutoff did not yield a significant difference in postoperative complication rates between the groups (17% vs. 27%, p = 0.100) (Table 1 ). Patients with tumors ≤ 3 cm had a higher eGFR on postoperative days 1 and 7 compared to those with tumors > 3 cm (Fig. 2 a). The group with a cutoff tumor diameter > 3 cm showed a significant decrease in eGFR at all assessed points after surgery compared to the group with a smaller diameter (Fig. 2 b). Conversely, when using a 4 cm cutoff, no clear distinction was observed between patients with decreased kidney function post-surgery (Fig. 2 c, d). Table 1. Characteristics of patients and background comparison between groups at 3 cm and 4 cm cutoff diameters Predicting efficiencies for perioperative and cancer outcomes A cutoff diameter of 3 cm more accurately distinguished operative time (area under the curve [AUC] 0.666), WIT (AUC 0.616), EBL (AUC 0.570), total intraoperative complications (AUC 0.575), and trifecta achievement (AUC 0.612) after receiver operating characteristic (ROC) analysis to calculate AUC (Table 2 ). Regarding cancer outcomes, the predictive efficiency of postoperative recurrence was superior with a 3 cm cutoff compared to a 4 cm cutoff (AUC 0.575 vs. 0.451, p = 0.037) (Table 2 ). Table 2 AUC value to predict perioperative complications in 3 cm and 4 cm cutoff diameters AUC Cutoff diameter 3 cm 4cm p Perioperative complication Total 0.575 0.451 0.037 Grade 1 0.570 0.406 0.143 Grade 2 0.569 0.486 0.293 Grade 3 0.554 0.463 0.413 Recurrence 0.586 0.600 0.913 AUC, area under the curve Discussion In this study, we analyzed 300 RALPN cases to compare outcomes using cutoffs of 4 cm and 3 cm. A tumor diameter ≤ 3 cm was associated with fewer complications and better postoperative eGFR; however, it had no impact on recurrence rates. ROC analysis demonstrated improved predictive ability for complications using the 3 cm cutoff. Thus, a 3 cm threshold may more precisely predict postoperative renal function and complications. Historically, the TNM classification was established and modified to predict prognosis and survival outcome 1 . Survival outcomes are primarily influenced by tumor biology, diagnostic modalities, and treatment efficacy. For instance, T1 was not divided into T1a and T1b before the TNM classification in 1997 17 . At that time, most kidney cancers, ranging from localized small tumors to invasive tumors with metastasis, were managed using total nephrectomy. However, PN was accepted as the ideal management for patients with SRM, and T1 was classified according to the 2002 classification 18 . Minimally invasive treatments, including cryoablation and RFA, have demonstrated excellent outcomes for tumors < 3 cm, with low recurrence rates, sparking discussions around further refining the cutoff diameter of T1 19,20 . In our study, the 3 cm cutoff was better at predicting perioperative complications and postoperative kidney function than the 4 cm cutoff. These results support considering a 3 cm threshold, even in patients treated with RALPN and minimally invasive treatments. Several factors have been suggested as predictors of kidney function after RALPN. Large tumors are well-known risk factors for kidney function decline because the larger the tumor, the greater the resected normal parenchyma that accumulates in patients treated with RALPN 9 . Volumetric analysis can accurately calculate the volume of the kidney tumor and the lost parenchyma 21 . However, volumetric analysis has never been the standard evaluation method used in general hospitals. Ohsugi et al. reported that tumor volume could predict kidney function decline after RALPN, using the calculated tumor volume extracted from a three-dimensional CT scan 22 . The threshold volume was 14.11 cm 3 , associated with > 20% eGFR decline, which corresponds to a 3 cm tumor diameter 22 . This report supports our findings, suggesting that a 3-cm diameter can be used to predict a significant decline in kidney function. To predict perioperative complications, the RENAL nephrometry score and other predictive models, such as the PADUA, C-index, and SPARE, are commonly used in patients with RCC treated with RALPN 23 , 24 . However, these models were established from the data of patients with kidney cancer treated with laparoscopic PN and may not be ideal for predicting the outcomes of patients with RCC treated with RALPN. Khene et al. analyzed the utility of predictive models (RENAL, PADUA, and SPARE) and tumor size in predicting complications using ROC-derived AUC 25 . Interestingly, only tumor size predicted overall complications, with an AUC of 58%, similar to other models with AUCs of 57–59%. Additionally, a 3 cm cutoff may be applied to the prediction of perioperative complications in this report 25 . The trifecta is thought to integrate the surgical quality of RALPN 26 . Bergero et al. showed that a 3 cm cutoff might be a better predictor of trifecta achievement (p = 0.001) than the clinical T1 classification, that is, a 4 cm cutoff (p = 0.003) 27 . This report also supports the assertion that a cutoff diameter of 3 cm can more accurately predict the quality of RALPN. Taken together, a tumor diameter of 3 cm may serve as a more effective cutoff value for predicting treatment outcomes in both minimally invasive management and RALPN. Our study has some limitations. First, it was retrospective and conducted at a single institution. Second, the sample size was relatively small, and not all patients had their kidney function assessed at every follow-up point. Third, complex cases, such as hilar tumors, might be excluded from surgical consideration by attending physicians, even in patients with tumors ≤ 3 cm in diameter. This selection bias might have influenced the results in unexpected ways. Hence, future research should involve larger, multi-center studies with regular kidney function assessments at every follow-up. Including complex cases, such as hilar tumors, will help minimize selection bias and provide more comprehensive insights into treatment outcomes for patients with tumors ≤ 3 cm. Expanding these studies will improve the generalizability and accuracy of clinical guidelines. Conclusions Our findings indicate that a tumor diameter of 3 cm is a more effective cutoff for predicting postoperative outcomes, including complications, renal function decline, and recurrence risk, compared to a 4 cm threshold. Declarations Data availability statement Data presented in this study are available upon request from the corresponding author. Funding This study was supported by a Grant-in-Aid for Scientific Research from Japan (Grant No. 24K12502). Author information 1 Department of Urology, Akita University Graduate School of Medicine, Japan Ryohei Yamamoto, Kazuyuki Numakura, Yu Aoyama, Keisuke Okubo, Hajime Sasagawa, Kanami Mori, Yuya Sekine, Hiromi Sato, Mizuki Kobayashi, Mitsuru Saito, Shintaro Narita, and Tomonori Habuchi 2 Department of Renal and Urologic Surgery, Asahikawa Medical University, Japan Kazuyuki Numakura Contributions RY: Data collection, Data analysis, Manuscript writing/editing, Protocol/project development (investigation, visualization). YA: Protocol/project development (conceptualization, methodology), Data collection, Data analysis, Manuscript writing/editing. KN: Protocol/project development (conceptualization, methodology, software), Data analysis, Manuscript writing/editing. KO: Data collection, Data analysis. HS: Data collection, Data analysis. KM: Data collection, Data analysis. YS: Data collection, Data analysis. HS: Data collection, Data analysis. MK: Data collection, Data analysis. MS: Data collection, Data analysis. SN: Data collection, Data analysis. TH: Protocol/project development (conceptualization, supervision), Manuscript writing/editing. Corresponding author Please direct all correspondence to Kazuyuki Numakura. Ethics Declarations Competing interests The authors have no conflict of interest to declare. Ethics approval and consent to participate Written informed consent was obtained from each participant in accordance with the principles of the Declaration of Helsinki. Each patient or the patient’s family was fully informed of the investigational nature of the study and provided written informed consent. The study protocol was approved by the Ethics Committee of Akita University Hospital. Consent for publication Not applicable. References Elkassem AA, Allen BC, Sharbidre KG et al (2021) Update on the role of imaging in clinical staging and restaging of renal cell carcinoma based on the AJCC 8th edition, from the AJR special series on cancer staging. AJR Am J Roentgenol 217:541–555. doi: 10.2214/AJR.21.25493 Ficarra V, Novara G, Galfano A et al (2004) Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. Eur Urol 46:559–564. doi: 10.1016/j.eururo.2004.07.002 Ljungberg B, Albiges L, Abu-Ghanem Y et al (2022) European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol 82:399–410. doi: 10.1016/j.eururo.2022.03.006 Zini L, Perrotte P, Capitanio U et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115:1465–1471. doi: 10.1002/cncr.24035 Tan HJ, Norton EC, Ye Z et al (2012) Long-term survival following partial vs. radical nephrectomy among older patients with early stage kidney cancer. JAMA 307:1629–1635. doi: 10.1001/jama.2012.475 Capitanio U, Terrone C, Antonelli A et al (2015) Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol 67:683–689. doi: 10.1016/j.eururo.2014.09.027 Brennan S, Watson DL, Rudd DM et al (2023) Kidney growth following preterm birth: evaluation with renal parenchyma ultrasonography. Pediatr Res 93:1302–1306. doi: 10.1038/s41390-022-01970-8 Yamamoto R, Numakura K, Kobayashi M et al (2024) Predictive factors of renal function after robot-assisted partial nephrectomy in clinical T1b tumors. J Robot Surg 18:154. doi: 10.1007/s11701-024-01848-3 Numakura K, Kobayashi M, Koizumi A et al (2022) Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon's experience. World J Surg Oncol 20:202. doi: 10.1186/s12957-022-02669-0 Huang RS, Chow R, Benour A et al (2025) Comparative efficacy and safety of ablative therapies in the management of primary localized renal cell carcinoma: a systematic review and meta-analysis. Lancet Oncol 26:387–398. doi: 10.1016/S1470-2045(24)00731-9 Schaarschmidt BM, Zensen S, Kesch C et al (2025) Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy. Eur Radiol 35:1723–1731. doi: 10.1007/s00330-024-11343-w Miyazaki S, Fujihara A, Hongo F et al (2025) Ten years of experience in percutaneous cryoablation for small renal masses in patients aged >/= 80 years. Eur J Surg Oncol 51:109638. doi: 10.1016/j.ejso.2025.109638 Yang B, Zheng Y, Zheng M et al (2024) Partial nephrectomy versus radiofrequency ablation in patients with cT1a renal cell carcinoma: a surveillance, epidemiology, end results (SEER) analysis. Medicine (Baltimore) 103:e40721. doi: 10.1097/MD.0000000000040721 Johnson BA, Sorokin I, Cadeddu JA (2019) Ten-year outcomes of renal tumor radiofrequency ablation. J Urol 201:251–258. doi: 10.1016/j.juro.2018.08.045 Tepeler A, Resorlu B, Sahin T et al (2014) Categorization of intraoperative ureteroscopy complications using modified Satava classification system. World J Urol 32:131–136. doi: 10.1007/s00345-013-1054-y Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196. doi: 10.1097/SLA.0b013e3181b13ca2 Gettman MT, Blute ML, Spotts B et al (2001) Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91:354–1361. doi: 10.1002/1097-0142(20010115)91:23.0.co;2-9 Salama ME, Guru K, Stricker H et al (2005) pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol 173:1492–1495. doi: 10.1097/01.ju.0000154693.68717.12 Capitanio U, Bedke J, Albiges L et al (2023) A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology Guidelines Panel. Eur Urol 83:3–5. doi: 10.1016/j.eururo.2022.09.026 Tang Y, Hu X, Wu K et al (2023) Re: Capitanio U, Bedke J, Albiges, et al. Renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3–5. Eur Urol 83:e73. doi: 10.1016/j.eururo.2022.11.026 Kanda S, Inoue T, Nakajima S et al (2022) Comparison of parenchymal volume loss assessed by three-dimensional computed tomography volumetry and renal functional recovery between conventional and robot-assisted laparoscopic partial nephrectomy. Asian J Endosc Surg 15:63–69. doi: 10.1111/ases.12966 . Ohsugi H, Akiyama K, Taniguchi H et al (2021) Tumor volume and tumor crossing of the axial renal midline predict renal function after robotic partial nephrectomy. Sci Rep 11:22526. doi: 10.1111/ases.12966 Hu C, Sun J, Zhang Z et al (2021) Parallel comparison of R.E.N.A.L., PADUA, and C-index scoring systems in predicting outcomes after partial nephrectomy: a systematic review and meta-analysis. Cancer Med 10:5062–5077. doi: 10.1002/cam4.4047 Ficarra V, Porpiglia F, Crestani A et al (2019) The Simplified PADUA REnal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. BJU Int 124:621–628. doi: 10.1111/bju.14772 Khene ZE, Mazouin C, Larcher A et al (2022) Predicting complications after robotic partial nephrectomy: back to simplicity. Eur Urol Focus 8:777–783. doi: 10.1016/j.euf.2021.04.017 Masui K, Matsuoka T, Kono J et al (2023) Analysis of trifecta outcomes in a single center with robot-assisted partial nephrectomy for T1b renal tumors. Asian J Endosc Surg 16:441–446. doi: 10.1111/ases.13182 Bergero MA, Costa L, Modina P et al (2022) Analysis of tecta results in a single-center experience with retroperitoneoscopic partial nephrectomy: an observational study. Arch Esp Urol 75:453–458. doi: 10.56434/j.arch.esp.urol.20227505.66 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 12 Sep, 2025 Read the published version in Journal of Robotic Surgery → Version 1 posted Editorial decision: Revision requested 24 Aug, 2025 Reviews received at journal 24 Aug, 2025 Reviews received at journal 23 Aug, 2025 Reviewers agreed at journal 22 Aug, 2025 Reviewers agreed at journal 18 Aug, 2025 Reviewers agreed at journal 17 Aug, 2025 Reviewers agreed at journal 16 Aug, 2025 Reviewers agreed at journal 16 Aug, 2025 Reviewers invited by journal 16 Aug, 2025 Editor assigned by journal 16 Aug, 2025 Submission checks completed at journal 04 Aug, 2025 First submitted to journal 03 Aug, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7281968","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":504866068,"identity":"4eda6030-dc70-44fd-af44-54aa832366d3","order_by":0,"name":"Ryohei Yamamoto","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Ryohei","middleName":"","lastName":"Yamamoto","suffix":""},{"id":504866069,"identity":"2dd16574-6486-49e2-8875-bc87ec46ea3d","order_by":1,"name":"Kazuyuki Numakura","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0klEQVRIiWNgGAWjYFACxscPPlSw1fczMDZ8IFILs5nhjDN8jDMbGBtnHCBSi4E0b4sc44YDDIzEaTFnT2YwnNlgxmx8u7mx+WMbgzy/GAGNlj2PGR583JHGZnbnYGPDwTag/tkJ+LUY3Mg/YDjzzDEesxuJ7Q+AWhIMbhPUkswgzdv2X8J4RiLYFqK1sBkYSBCt5cxjNmAgsyVI3ABqOXNOggi/HE9mBkVlAv+M9IcNFWU28vzSBLQwMCArYGSTIKQcXQvDH2J0jIJRMApGwUgDADnUTcx9Ti3RAAAAAElFTkSuQmCC","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":true,"prefix":"","firstName":"Kazuyuki","middleName":"","lastName":"Numakura","suffix":""},{"id":504866071,"identity":"de27cc81-2461-4478-9ffa-df3412b14df9","order_by":2,"name":"Yu Aoyama","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Aoyama","suffix":""},{"id":504866072,"identity":"ad0fb4b6-27ce-4e38-8a7b-ec780a37053b","order_by":3,"name":"Keisuke Okubo","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Keisuke","middleName":"","lastName":"Okubo","suffix":""},{"id":504866074,"identity":"3eda46fd-0b4f-4a3e-ba07-394275a40b3f","order_by":4,"name":"Hajime Sasagawa","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Hajime","middleName":"","lastName":"Sasagawa","suffix":""},{"id":504866075,"identity":"adfcebd1-960c-4148-a670-642ebc9f8b2f","order_by":5,"name":"Kanami Mori","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Kanami","middleName":"","lastName":"Mori","suffix":""},{"id":504866076,"identity":"fc2085e0-cf60-4c27-8bbc-c900939eb0b6","order_by":6,"name":"Yuya Sekine","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yuya","middleName":"","lastName":"Sekine","suffix":""},{"id":504866079,"identity":"9cbf63ab-55c3-4f20-83a8-713c7a656d89","order_by":7,"name":"Hiromi Sato","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Hiromi","middleName":"","lastName":"Sato","suffix":""},{"id":504866080,"identity":"76ed6569-7699-4b18-a943-1b34c329a689","order_by":8,"name":"Mizuki Kobayashi","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Mizuki","middleName":"","lastName":"Kobayashi","suffix":""},{"id":504866082,"identity":"a5b146a1-d032-4a75-b613-7909d9b03afb","order_by":9,"name":"Mitsuru Saito","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Mitsuru","middleName":"","lastName":"Saito","suffix":""},{"id":504866083,"identity":"24cb8188-13e6-4a9d-b3f6-55bfda5f3e4d","order_by":10,"name":"Shintaro Narita","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Shintaro","middleName":"","lastName":"Narita","suffix":""},{"id":504866084,"identity":"2f950c45-8e6b-4fce-88d5-76f1df23338f","order_by":11,"name":"Tomonori Habuchi","email":"","orcid":"","institution":"Akita University Graduate School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Tomonori","middleName":"","lastName":"Habuchi","suffix":""}],"badges":[],"createdAt":"2025-08-03 07:53:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7281968/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7281968/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s11701-025-02775-7","type":"published","date":"2025-09-12T15:57:03+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":89978050,"identity":"cd0cad83-c0bf-4e0e-a120-1f85b2b3690d","added_by":"auto","created_at":"2025-08-27 06:13:26","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":9288,"visible":true,"origin":"","legend":"\u003cp\u003ePatient selection diagram of 335 RCC patients treated with RALPN. We selected 300 patients who were treated with RALPN in this study\u003c/p\u003e\n\u003cp\u003eRCC, renal cell carcinoma; RALPN, robot-assisted laparoscopic partial nephrectomy; RN, radical nephrectomy\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-7281968/v1/47cb8d9b2c826f7783731735.png"},{"id":89978051,"identity":"353af455-2077-4be3-a49a-f07bf9f33a1a","added_by":"auto","created_at":"2025-08-27 06:13:26","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":17474,"visible":true,"origin":"","legend":"\u003cp\u003eChanges in preoperative and postoperative estimated glomerular filtration rates (eGFR) for cutoff diameters of 4 cm (a) and 3 cm (b) measured at 0 days, 1 day, 1 week, 1 month, 6 months, and 1 year after robot-assisted laparoscopic partial nephrectomy The change rates of postoperative eGFR for cutoff diameters of 4 cm (c) and 3 cm (d) are displayed at the same time intervals: 0 days, 1 day, 1 week, 1 month, 6 months, and 1 year after the procedure\u003c/p\u003e\n\u003cp\u003ePOD, postoperative day; POM, postoperative month; POY, postoperative year\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-7281968/v1/4fe503f00da5972fe26436ad.png"},{"id":91817642,"identity":"fc17984c-ebcb-4cac-a9d6-712ab001999b","added_by":"auto","created_at":"2025-09-22 06:59:57","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":730132,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7281968/v1/185b320a-48b7-4193-9873-d5da27bc7e49.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Reassessment of T1a cutoff for kidney cancer in the robotic era","fulltext":[{"header":"Introduction","content":"\u003cp\u003eThe Tumour, Node, and Metastasis (TNM) classification based on clinical findings is a reasonable approach for predicting the outcomes of patients with cancer\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Historically, the TNM classification for renal cell carcinoma (RCC) has been revised not only to reflect natural history but also in response to advances in diagnostic modalities and treatment options. For instance, in the 2002 Union for International Cancer Control revision, the T1 category was subdivided into T1a and T1b using a 4 cm cutoff diameter, reflecting the increasing number of newly diagnosed organ-confined kidney tumors resulting from the development of imaging modalities such as computed tomography and ultrasonography\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. The current TNM classification more effectively discriminates between cancer outcomes.\u003c/p\u003e\u003cp\u003eFor patients with T1 kidney cancer, partial nephrectomy (PN) is equivalent to radical nephrectomy (RN) in terms of cancer control\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Moreover, several studies have demonstrated that overall survival rates are better in patients treated with PN than in those treated with RN, largely due to higher comorbidity rates, such as cardiovascular events, in the RN group\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Following the introduction of a robotic platform for kidney surgery, robot-assisted laparoscopic partial nephrectomy (RALPN) has become the standard procedure for T1 RCC\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Robotic surgery has obvious advantages over pure laparoscopic nephrectomy, such as more precise resection and proper parenchyma suturing\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. It also provides favorable oncological outcomes, preserves renal function, and reduces complications\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eRecent advancements in less-invasive procedures for patients with small renal masses (SRM) may shift management trends for RCC and improve the life expectancy of patients\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Cryoablation is a minimally invasive treatment for kidney cancer, particularly indicated for SRMs, especially those 3 cm or less, as it provides excellent local control and low recurrence rates\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Cryoablation is often considered in patients with comorbidities, poor surgical candidates, or those with bilateral or multiple tumors\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Radiofrequency ablation (RFA) is a minimally invasive treatment for small renal tumors that offers nephron-sparing benefits with lower morbidity compared to surgery. It utilizes thermal energy to destroy cancer cells and is particularly useful for patients who are unsuitable for surgery due to comorbidities\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. RFA is best suited for older patients, those with single kidneys, bilateral tumors, or multiple comorbidities, and is highly effective for tumors\u0026thinsp;\u0026le;\u0026thinsp;3 cm, providing good local control and low recurrence rates\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eThese less-invasive techniques, such as cryoablation and RFA, may represent a paradigm shift in managing SRM and might influence clinical decisions. However, little is known about how different cutoff diameters affect the outcomes of RALPN, which remains the mainstay for managing SRM. Thus, in this study, we aimed to clarify the impact of changing the T1 cutoff from 4 cm to 3 cm in the context of RALPN.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003eOur institute performed 335 RALPNs for clinical T1 kidney tumors between November 2013 and April 2024. Of these, 300 cases were included in this study after excluding cases of conversion to RN, bilateral tumors, benign histology, and those without follow-up computed tomography (CT) scans (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Clinical staging and RENAL scores were determined based on preoperative CT scans.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eRALPN was performed using either a standard transperitoneal or retroperitoneal approach, depending on the patient\u0026rsquo;s history of transabdominal surgery, tumor size, and tumor location. PN was performed by clamping the main trunk of the renal artery with a bulldog clamp. The renal vein was clamped in renal hilar tumors. Tumors with a 5-mm surgical margin were resected under 15 mmHg CO\u003csub\u003e2\u003c/sub\u003e pressure; preparation of the renal capsule and tumor surface was conducted at 10 mmHg CO\u003csub\u003e2\u003c/sub\u003e pressure. Inner medullary hemostatic sutures were performed using a running barbed suture, followed by early unclamping and additional hemostatic sutures. Renorrhaphy of the inner and outer layers was performed using 2\u0026thinsp;\u0026minus;\u0026thinsp;0 STRATAFIX\u0026trade; Spiral PDS\u0026trade; Plus (Ethicon, Raritan, NJ, USA) or 3\u0026thinsp;\u0026minus;\u0026thinsp;0 V-Loc\u0026trade; (Medtronic, Dublin, Ireland), depending on the tumor size and location. All specimens were retrieved using an ENDOPOUCH\u0026trade; RETRIEVER\u0026trade; Specimen bag (AutoSuture, Hampshire, UK) through a camera port. Intra- and postoperative complications were categorized based on the Satava\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e and Clavien\u0026ndash;Dindo\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e classification systems, respectively, as major or minor complications, and major complications were defined as grade II or higher.\u003c/p\u003e\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eStatistical analysis\u003c/h2\u003e\u003cp\u003eAll data are expressed as the median (interquartile range [IQR]). Clinical risk factors associated with longer warm ischemia time (WIT) were screened using univariate analysis. Factors with a p-value of \u0026lt;\u0026thinsp;0.1 in the univariate analysis were confirmed using logistic regression analysis. All p-values were two-sided, and p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant. All statistical analyses were performed using R software (version 4.4.1; The R Foundation for Statistical Computing, Vienna, Austria).\u003c/p\u003e\u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eOverall characteristics of the patients treated using RALPN\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTable \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e presents the baseline characteristics of enrolled patients. In this cohort, 73% of patients were male, with a median age of 65 years (IQR, 57\u0026ndash;71 years). The median body mass index was 24.5 kg/m\u0026sup2; (IQR, 22.5\u0026ndash;27.2). The median tumor diameter and RENAL nephrectomy score were 30 mm (IQR, 23\u0026ndash;37) and 7 (IQR, 6\u0026ndash;8), respectively. The median estimated glomerular filtration rate (eGFR) at baseline was 65.5 mL/min/1.73 m\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e (IQR, 55.5\u0026ndash;75.2) (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). The median operative time and WIT were 226 min (IQR, 200\u0026ndash;255) and 17 min (IQR, 14\u0026ndash;20), respectively. The median estimated blood loss (EBL) was 55 mL (IQR, 20\u0026ndash;152). A trifecta was achieved in 237 patients (79%), and Clavien\u0026ndash;Dindo grade 3A or higher complications occurred in 15 patients (5%). There were no positive cases with resection margins, and five cases (2%) of postoperative recurrence occurred. In the groups below each cutoff diameter, the operative time and WIT were shorter, and the bleeding volume was smaller.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption\u003e\n \u003cdiv class=\"CaptionNumber\"\u003e\u003cbr\u003e\u003c/div\u003e\n \u003c/caption\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cstrong\u003eComparison of the cutoff diameter between 4 cm and 3 cm\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhen the cutoff tumor diameter was set at 3 cm, the incidence of postoperative complications was significantly lower in the \u0026le;\u0026thinsp;3 cm group compared to the \u0026gt;\u0026thinsp;3 cm group (15% vs. 25%, p\u0026thinsp;=\u0026thinsp;0.04). However, using a 4 cm cutoff did not yield a significant difference in postoperative complication rates between the groups (17% vs. 27%, p\u0026thinsp;=\u0026thinsp;0.100) (Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). Patients with tumors\u0026thinsp;\u0026le;\u0026thinsp;3 cm had a higher eGFR on postoperative days 1 and 7 compared to those with tumors\u0026thinsp;\u0026gt;\u0026thinsp;3 cm (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ea). The group with a cutoff tumor diameter\u0026thinsp;\u0026gt;\u0026thinsp;3 cm showed a significant decrease in eGFR at all assessed points after surgery compared to the group with a smaller diameter (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eb). Conversely, when using a 4 cm cutoff, no clear distinction was observed between patients with decreased kidney function post-surgery (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003ec, d).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e1.\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eCharacteristics of patients and background comparison between groups at 3 cm and 4 cm cutoff diameters\u003c/p\u003e\n\u003cdiv id=\"_com_1\" language=\"JavaScript\"\u003e\n \u003cp\u003e\u003cimg width=\"930\" height=\"465\" src=\"data:image/emf;base64,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\" alt=\"image\"\u003e\u003cbr\u003e\u003c/p\u003e\n\u003c/div\u003e\n\n\u003cp\u003e\u003cstrong\u003ePredicting efficiencies for perioperative and cancer outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA cutoff diameter of 3 cm more accurately distinguished operative time (area under the curve [AUC] 0.666), WIT (AUC 0.616), EBL (AUC 0.570), total intraoperative complications (AUC 0.575), and trifecta achievement (AUC 0.612) after receiver operating characteristic (ROC) analysis to calculate AUC (Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e). Regarding cancer outcomes, the predictive efficiency of postoperative recurrence was superior with a 3 cm cutoff compared to a 4 cm cutoff (AUC 0.575 vs. 0.451, p\u0026thinsp;=\u0026thinsp;0.037) (Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab2\" border=\"1\"\u003e\n \u003ccaption\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eAUC value to predict perioperative complications in 3 cm and 4 cm cutoff diameters\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth colspan=\"2\" align=\"left\"\u003e\n \u003cp\u003eAUC\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eCutoff diameter\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003e3 cm\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003e4cm\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003ep\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePerioperative complication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eTotal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.575\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.451\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.037\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGrade 1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.570\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.406\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.143\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGrade 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.569\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.486\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.293\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eGrade 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.554\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.463\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.413\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRecurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.586\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.600\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\"\u003e\n \u003cp\u003e0.913\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003ctfoot\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\"\u003eAUC, area under the curve\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tfoot\u003e\n \u003c/table\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we analyzed 300 RALPN cases to compare outcomes using cutoffs of 4 cm and 3 cm. A tumor diameter\u0026thinsp;\u0026le;\u0026thinsp;3 cm was associated with fewer complications and better postoperative eGFR; however, it had no impact on recurrence rates. ROC analysis demonstrated improved predictive ability for complications using the 3 cm cutoff. Thus, a 3 cm threshold may more precisely predict postoperative renal function and complications.\u003c/p\u003e\u003cp\u003eHistorically, the TNM classification was established and modified to predict prognosis and survival outcome\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Survival outcomes are primarily influenced by tumor biology, diagnostic modalities, and treatment efficacy. For instance, T1 was not divided into T1a and T1b before the TNM classification in 1997\u003csup\u003e17\u003c/sup\u003e. At that time, most kidney cancers, ranging from localized small tumors to invasive tumors with metastasis, were managed using total nephrectomy. However, PN was accepted as the ideal management for patients with SRM, and T1 was classified according to the 2002 classification\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. Minimally invasive treatments, including cryoablation and RFA, have demonstrated excellent outcomes for tumors\u0026thinsp;\u0026lt;\u0026thinsp;3 cm, with low recurrence rates, sparking discussions around further refining the cutoff diameter of T1\u003csup\u003e19,20\u003c/sup\u003e. In our study, the 3 cm cutoff was better at predicting perioperative complications and postoperative kidney function than the 4 cm cutoff. These results support considering a 3 cm threshold, even in patients treated with RALPN and minimally invasive treatments.\u003c/p\u003e\u003cp\u003eSeveral factors have been suggested as predictors of kidney function after RALPN. Large tumors are well-known risk factors for kidney function decline because the larger the tumor, the greater the resected normal parenchyma that accumulates in patients treated with RALPN\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Volumetric analysis can accurately calculate the volume of the kidney tumor and the lost parenchyma\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. However, volumetric analysis has never been the standard evaluation method used in general hospitals. Ohsugi et al. reported that tumor volume could predict kidney function decline after RALPN, using the calculated tumor volume extracted from a three-dimensional CT scan\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. The threshold volume was 14.11 cm\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e, associated with \u0026gt;\u0026thinsp;20% eGFR decline, which corresponds to a 3 cm tumor diameter\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. This report supports our findings, suggesting that a 3-cm diameter can be used to predict a significant decline in kidney function.\u003c/p\u003e\u003cp\u003eTo predict perioperative complications, the RENAL nephrometry score and other predictive models, such as the PADUA, C-index, and SPARE, are commonly used in patients with RCC treated with RALPN\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e. However, these models were established from the data of patients with kidney cancer treated with laparoscopic PN and may not be ideal for predicting the outcomes of patients with RCC treated with RALPN. Khene et al. analyzed the utility of predictive models (RENAL, PADUA, and SPARE) and tumor size in predicting complications using ROC-derived AUC\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. Interestingly, only tumor size predicted overall complications, with an AUC of 58%, similar to other models with AUCs of 57\u0026ndash;59%. Additionally, a 3 cm cutoff may be applied to the prediction of perioperative complications in this report\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. The trifecta is thought to integrate the surgical quality of RALPN\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. Bergero et al. showed that a 3 cm cutoff might be a better predictor of trifecta achievement (p\u0026thinsp;=\u0026thinsp;0.001) than the clinical T1 classification, that is, a 4 cm cutoff (p\u0026thinsp;=\u0026thinsp;0.003)\u003csup\u003e27\u003c/sup\u003e. This report also supports the assertion that a cutoff diameter of 3 cm can more accurately predict the quality of RALPN.\u003c/p\u003e\u003cp\u003eTaken together, a tumor diameter of 3 cm may serve as a more effective cutoff value for predicting treatment outcomes in both minimally invasive management and RALPN.\u003c/p\u003e\u003cp\u003eOur study has some limitations. First, it was retrospective and conducted at a single institution. Second, the sample size was relatively small, and not all patients had their kidney function assessed at every follow-up point. Third, complex cases, such as hilar tumors, might be excluded from surgical consideration by attending physicians, even in patients with tumors\u0026thinsp;\u0026le;\u0026thinsp;3 cm in diameter. This selection bias might have influenced the results in unexpected ways. Hence, future research should involve larger, multi-center studies with regular kidney function assessments at every follow-up. Including complex cases, such as hilar tumors, will help minimize selection bias and provide more comprehensive insights into treatment outcomes for patients with tumors\u0026thinsp;\u0026le;\u0026thinsp;3 cm. Expanding these studies will improve the generalizability and accuracy of clinical guidelines.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eOur findings indicate that a tumor diameter of 3 cm is a more effective cutoff for predicting postoperative outcomes, including complications, renal function decline, and recurrence risk, compared to a 4 cm threshold.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData presented in this study are available upon request from the corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was supported by a Grant-in-Aid for Scientific Research from Japan (Grant No. 24K12502).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003e Department of Urology, Akita University Graduate School of Medicine, Japan\u003c/p\u003e\n\u003cp\u003eRyohei Yamamoto, Kazuyuki Numakura, Yu Aoyama, Keisuke Okubo, Hajime Sasagawa, Kanami Mori, Yuya Sekine, Hiromi Sato, Mizuki Kobayashi, Mitsuru Saito, Shintaro Narita, and Tomonori Habuchi\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e2\u003c/sup\u003e Department of Renal and Urologic Surgery, Asahikawa Medical University, Japan\u003c/p\u003e\n\u003cp\u003eKazuyuki Numakura\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRY: Data collection, Data analysis, Manuscript writing/editing, Protocol/project development (investigation, visualization).\u003c/p\u003e\n\u003cp\u003eYA: Protocol/project development (conceptualization, methodology), Data collection, Data analysis, Manuscript writing/editing.\u003c/p\u003e\n\u003cp\u003eKN: Protocol/project development (conceptualization, methodology, software), Data analysis, Manuscript writing/editing.\u003c/p\u003e\n\u003cp\u003eKO: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eHS: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eKM: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eYS: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eHS: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eMK: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eMS: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eSN: Data collection, Data analysis.\u003c/p\u003e\n\u003cp\u003eTH: Protocol/project development (conceptualization, supervision), Manuscript writing/editing.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCorresponding author\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePlease direct all correspondence to Kazuyuki Numakura.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics Declarations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no conflict of interest to declare.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWritten informed consent was obtained from each participant in accordance with the principles of the Declaration of Helsinki. Each patient or the patient\u0026rsquo;s family was fully informed of the investigational nature of the study and provided written informed consent. The study protocol was approved by the Ethics Committee of Akita University Hospital.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cdiv id=\"_com_4\" language=\"JavaScript\"\u003e\u003cbr\u003e\u003c/div\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eElkassem AA, Allen BC, Sharbidre KG et al (2021) Update on the role of imaging in clinical staging and restaging of renal cell carcinoma based on the AJCC 8th edition, from the AJR special series on cancer staging. AJR Am J Roentgenol 217:541\u0026ndash;555. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2214/AJR.21.25493\u003c/span\u003e\u003cspan address=\"10.2214/AJR.21.25493\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFicarra V, Novara G, Galfano A et al (2004) Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. Eur Urol 46:559\u0026ndash;564. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2004.07.002\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2004.07.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLjungberg B, Albiges L, Abu-Ghanem Y et al (2022) European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol 82:399\u0026ndash;410. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2022.03.006\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2022.03.006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZini L, Perrotte P, Capitanio U et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115:1465\u0026ndash;1471. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/cncr.24035\u003c/span\u003e\u003cspan address=\"10.1002/cncr.24035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTan HJ, Norton EC, Ye Z et al (2012) Long-term survival following partial vs. radical nephrectomy among older patients with early stage kidney cancer. JAMA 307:1629\u0026ndash;1635. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2012.475\u003c/span\u003e\u003cspan address=\"10.1001/jama.2012.475\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCapitanio U, Terrone C, Antonelli A et al (2015) Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol 67:683\u0026ndash;689. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2014.09.027\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2014.09.027\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrennan S, Watson DL, Rudd DM et al (2023) Kidney growth following preterm birth: evaluation with renal parenchyma ultrasonography. Pediatr Res 93:1302\u0026ndash;1306. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41390-022-01970-8\u003c/span\u003e\u003cspan address=\"10.1038/s41390-022-01970-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYamamoto R, Numakura K, Kobayashi M et al (2024) Predictive factors of renal function after robot-assisted partial nephrectomy in clinical T1b tumors. J Robot Surg 18:154. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-024-01848-3\u003c/span\u003e\u003cspan address=\"10.1007/s11701-024-01848-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNumakura K, Kobayashi M, Koizumi A et al (2022) Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon's experience. World J Surg Oncol 20:202. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12957-022-02669-0\u003c/span\u003e\u003cspan address=\"10.1186/s12957-022-02669-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHuang RS, Chow R, Benour A et al (2025) Comparative efficacy and safety of ablative therapies in the management of primary localized renal cell carcinoma: a systematic review and meta-analysis. Lancet Oncol 26:387\u0026ndash;398. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1470-2045(24)00731-9\u003c/span\u003e\u003cspan address=\"10.1016/S1470-2045(24)00731-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSchaarschmidt BM, Zensen S, Kesch C et al (2025) Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy. Eur Radiol 35:1723\u0026ndash;1731. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00330-024-11343-w\u003c/span\u003e\u003cspan address=\"10.1007/s00330-024-11343-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMiyazaki S, Fujihara A, Hongo F et al (2025) Ten years of experience in percutaneous cryoablation for small renal masses in patients aged \u0026gt;/= 80 years. Eur J Surg Oncol 51:109638. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ejso.2025.109638\u003c/span\u003e\u003cspan address=\"10.1016/j.ejso.2025.109638\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYang B, Zheng Y, Zheng M et al (2024) Partial nephrectomy versus radiofrequency ablation in patients with cT1a renal cell carcinoma: a surveillance, epidemiology, end results (SEER) analysis. Medicine (Baltimore) 103:e40721. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/MD.0000000000040721\u003c/span\u003e\u003cspan address=\"10.1097/MD.0000000000040721\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJohnson BA, Sorokin I, Cadeddu JA (2019) Ten-year outcomes of renal tumor radiofrequency ablation. J Urol 201:251\u0026ndash;258. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.juro.2018.08.045\u003c/span\u003e\u003cspan address=\"10.1016/j.juro.2018.08.045\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTepeler A, Resorlu B, Sahin T et al (2014) Categorization of intraoperative ureteroscopy complications using modified Satava classification system. World J Urol 32:131\u0026ndash;136. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00345-013-1054-y\u003c/span\u003e\u003cspan address=\"10.1007/s00345-013-1054-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eClavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187\u0026ndash;196. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/SLA.0b013e3181b13ca2\u003c/span\u003e\u003cspan address=\"10.1097/SLA.0b013e3181b13ca2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGettman MT, Blute ML, Spotts B et al (2001) Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91:354\u0026ndash;1361. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/1097-0142(20010115)91:2\u0026lt;354::aid-cncr1009\u0026gt;3.0.co;2-9\u003c/span\u003e\u003cspan address=\"10.1002/1097-0142(20010115)91:2%3C354::aid-cncr1009%3E3.0.co;2-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSalama ME, Guru K, Stricker H et al (2005) pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol 173:1492\u0026ndash;1495. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/01.ju.0000154693.68717.12\u003c/span\u003e\u003cspan address=\"10.1097/01.ju.0000154693.68717.12\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCapitanio U, Bedke J, Albiges L et al (2023) A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology Guidelines Panel. Eur Urol 83:3\u0026ndash;5. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2022.09.026\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2022.09.026\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTang Y, Hu X, Wu K et al (2023) Re: Capitanio U, Bedke J, Albiges, et al. Renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3\u0026ndash;5. Eur Urol 83:e73. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2022.11.026\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2022.11.026\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKanda S, Inoue T, Nakajima S et al (2022) Comparison of parenchymal volume loss assessed by three-dimensional computed tomography volumetry and renal functional recovery between conventional and robot-assisted laparoscopic partial nephrectomy. Asian J Endosc Surg 15:63\u0026ndash;69. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ases.12966\u003c/span\u003e\u003cspan address=\"10.1111/ases.12966\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eOhsugi H, Akiyama K, Taniguchi H et al (2021) Tumor volume and tumor crossing of the axial renal midline predict renal function after robotic partial nephrectomy. Sci Rep 11:22526. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ases.12966\u003c/span\u003e\u003cspan address=\"10.1111/ases.12966\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHu C, Sun J, Zhang Z et al (2021) Parallel comparison of R.E.N.A.L., PADUA, and C-index scoring systems in predicting outcomes after partial nephrectomy: a systematic review and meta-analysis. Cancer Med 10:5062\u0026ndash;5077. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/cam4.4047\u003c/span\u003e\u003cspan address=\"10.1002/cam4.4047\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFicarra V, Porpiglia F, Crestani A et al (2019) The Simplified PADUA REnal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. BJU Int 124:621\u0026ndash;628. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/bju.14772\u003c/span\u003e\u003cspan address=\"10.1111/bju.14772\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKhene ZE, Mazouin C, Larcher A et al (2022) Predicting complications after robotic partial nephrectomy: back to simplicity. Eur Urol Focus 8:777\u0026ndash;783. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.euf.2021.04.017\u003c/span\u003e\u003cspan address=\"10.1016/j.euf.2021.04.017\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMasui K, Matsuoka T, Kono J et al (2023) Analysis of trifecta outcomes in a single center with robot-assisted partial nephrectomy for T1b renal tumors. Asian J Endosc Surg 16:441\u0026ndash;446. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/ases.13182\u003c/span\u003e\u003cspan address=\"10.1111/ases.13182\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBergero MA, Costa L, Modina P et al (2022) Analysis of tecta results in a single-center experience with retroperitoneoscopic partial nephrectomy: an observational study. Arch Esp Urol 75:453\u0026ndash;458. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.56434/j.arch.esp.urol.20227505.66\u003c/span\u003e\u003cspan address=\"10.56434/j.arch.esp.urol.20227505.66\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"journal-of-robotic-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jors","sideBox":"Learn more about [Journal of Robotic Surgery](http://link.springer.com/journal/11701)","snPcode":"11701","submissionUrl":"https://submission.nature.com/new-submission/11701/3","title":"Journal of Robotic Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"kidney cancer, clinical T1a classification, partial nephrectomy, robotic surgery","lastPublishedDoi":"10.21203/rs.3.rs-7281968/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7281968/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIn 2002, the renal cancer T classification was revised by dividing T1 into T1a and T1b at a 4 cm cutoff. However, local treatment using minimally invasive procedures resulted in better outcomes for tumors smaller than 3 cm, leading the European Association of Urology guideline committee to propose a 3 cm cutoff for T1a/b. Nonetheless, the impact of changing the T1 cutoff on robot-assisted partial nephrectomy (RALPN) has not been fully investigated. This study included 300 out of 335 patients with clinical stage T1 disease who underwent RALPN at our institution between November 2013 and April 2024. We evaluated the discriminative performance of clinical outcomes in each group using tumor diameter cutoffs of 4 and 3 cm. Using a 3 cm cutoff, patients with tumors\u0026thinsp;\u0026ge;\u0026thinsp;3 cm showed a greater decline in estimated glomerular filtration rate (eGFR) (-9.6% vs. -4.9%, p\u0026thinsp;=\u0026thinsp;0.003) and a higher incidence of complications (25% vs. 15%, p\u0026thinsp;=\u0026thinsp;0.040) compared to those with smaller tumors. With a 4 cm cutoff, differences in eGFR decline (-7.8% vs. -6.7%, p\u0026thinsp;=\u0026thinsp;0.134) and complications (27% vs. 17%, p\u0026thinsp;=\u0026thinsp;0.100) were not significant. The 3 cm cutoff more accurately predicted complications with a higher area under the curve (0.575 vs. 0.451, p\u0026thinsp;=\u0026thinsp;0.037). A 3 cm cutoff for the T classification of kidney cancer may more accurately predict postoperative renal function and the risk of complications.\u003c/p\u003e","manuscriptTitle":"Reassessment of T1a cutoff for kidney cancer in the robotic era","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-27 06:13:21","doi":"10.21203/rs.3.rs-7281968/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-08-24T17:11:23+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-24T16:35:37+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-23T07:35:57+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"58893452783440382858594450531822307311","date":"2025-08-22T20:57:24+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"180644904838044958701886306285378524109","date":"2025-08-18T19:32:45+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"194171520521359120102839197378509555708","date":"2025-08-18T01:47:39+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"311356909828619872868904901073816725502","date":"2025-08-17T03:04:17+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"70574108032626662737940593630129333305","date":"2025-08-16T20:30:43+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-08-16T15:35:31+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-08-16T15:32:22+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-08-04T13:54:09+00:00","index":"","fulltext":""},{"type":"submitted","content":"Journal of Robotic Surgery","date":"2025-08-03T07:37:54+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"journal-of-robotic-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jors","sideBox":"Learn more about [Journal of Robotic Surgery](http://link.springer.com/journal/11701)","snPcode":"11701","submissionUrl":"https://submission.nature.com/new-submission/11701/3","title":"Journal of Robotic Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"f0bae108-bc4d-46fa-97bf-69c152f3d29a","owner":[],"postedDate":"August 27th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-09-22T06:51:08+00:00","versionOfRecord":{"articleIdentity":"rs-7281968","link":"https://doi.org/10.1007/s11701-025-02775-7","journal":{"identity":"journal-of-robotic-surgery","isVorOnly":false,"title":"Journal of Robotic Surgery"},"publishedOn":"2025-09-12 15:57:03","publishedOnDateReadable":"September 12th, 2025"},"versionCreatedAt":"2025-08-27 06:13:21","video":"","vorDoi":"10.1007/s11701-025-02775-7","vorDoiUrl":"https://doi.org/10.1007/s11701-025-02775-7","workflowStages":[]},"version":"v1","identity":"rs-7281968","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7281968","identity":"rs-7281968","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}